Actively Recruiting
Evaluation of BCX17725 Safety, Tolerability, and Immune Response in Healthy Adults and People With Netherton Syndrome Using Single and Multiple Doses
Led by BioCryst Pharmaceuticals · Updated on 2026-08-27
78
Participants Needed
12
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating BCX17725 in a first-in-human Phase 11b trial to study its safety, tolerability, pharmacokinetics, and immune response. The study includes healthy adults and people with Netherton syndrome, a rare skin condition. The research aims to understand how BCX17725 works when given in different doses and forms to these groups. The study has four parts Parts 1 and 2 are randomized, placebo-controlled studies in healthy adults testing single and multiple ascending doses of BCX17725. Part 3 is an open-label study giving multiple doses to adults with Netherton syndrome. Part 4 also involves multiple doses of BCX17725 in adolescents and adults with Netherton syndrome over 12 weeks, followed by an 8-week safety follow-up. Participants will undergo screening and then receive either BCX17725 or placebo depending on the study part. Researchers will monitor safety through adverse events and measure drug levels in the blood. Effectiveness will be assessed by changes in skin severity scores and itch ratings in Netherton syndrome participants. Follow-up visits will continue after treatment to observe ongoing effects and safety for up to 20 weeks in some parts.
CONDITIONS
Brief Title
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
Research Team
B
BioCryst Pharmaceuticals, Inc.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here